Log Out Log Out

Ready for rescue

The first and only glucagon with nasal administration

BAQSIMITM is indicated for the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates.

BAQSIMI is indicated in children 4 years and above. BAQSIMI has not been studied in patients less than 4 years of age.

 

Baqsimi: Designed with serve hypoglycemia treatment in mind

  • Dry powder form of glucagon
  • Single use, pre-filled nasal device containing a 3 mg dose
  • Ready to use with no reconstitution or priming required
  • Does not need to be refrigerated
    • Can be stored up to 30°C (86°F) in the shrink-wrapped tube provided
  • Absorbed passively via the intranasal route—no inhalation required
  • BAQSIMI has a shelf life of 2 years from the date of manufacture
  • Each BAQSIMI device contains a single dose and is available as a 1-pack.

Formulation invented in Canada

  • Efficacy +

    BAQSIMI BEGAN RAISING MEAN PLASMA GLUCOSE AS EARLY AS 5 MINUTES IN PATIENTS AGES 4 TO <18

    Mean plasma glucose concentrations over time with BAQSIMI in patients ages 4 to <18

    BAQSIMI DEMONSTRATED COMPARABLE EFFICACY TO INJECTABLE GLUCAGON IN PEDIATRIC PATIENTS WITH TYPE 1 DIABETES

    Treatment success for BAQSIMI and injectable glucagon*

    Prior to treatment, insulin was used to reduce blood glucose levels. Treatment success was defined as the percentage of patients with a glucose increase of ≥1.1 mmol/L from the glucose nadir within 30 minutes of glucagon administration.

    Nasal congestion does not impact the absorption of BAQSIMI

    * Study IGBB was a randomized, multicenter, open-label clinical study that assessed BAQSIMI compared to intra-muscular glucagon in pediatric patients aged 4 years and older with type 1 diabetes. Insulin was used to reduce blood glucose levels, and glucagon was administered after glucose reached <4.4 mmol/L on the dosing day.
    † Patients aged 4 to <8 years (n=12), 8 to <12 years (n=12), and 12 to <18 years (n=12).
    ‡ Patients aged 4 to <8 years (n=6), 8 to <12 years (n=6), and 12 to <18 years (n=12).


    Click here to download the full study publication
  • Safety+

    BAQSIMI ADVERSE REACTIONS IN PEDIATRIC PATIENTS

    Adverse reactions (%) occurring in pediatric patients with an incidence of ≥5%

    Adverse Reactions BAQSIMI 3 mg
    (n=36) %
    INJECTABLE GLUCAGON weight based
    (n=24) %
    Gastrointestinal disorders
    Vomiting 30.6 37.5
    Nausea 16.7 33.3
    General disorders and administration site conditions
    Injection site discomfort 0 20.8
    Nervous system disorders
    Headache 25.0 12.5
    Respiratory, thoracic and mediastinal disorders
    Nasal discomfort 8.3 0
    Nasal congestion 5.6 0

Please note this link will take you to a website which is not part of LillyPro.ca.

Are you sure you want to
logout ?